Chief Strategy Officer
Henry has been working to transform
the way the biopharmaceutical industry
improves patient health for 23 years. Prior to Veeva,
Henry was chief commercial officer for PPD, where
he defined new models for the biotech and biophar-
maceutical industry to partner with contract research
organizations. These new models brought down the
cost and improved the speed of drug development.
Prior to PPD, Henry led Accenture’s life sciences
research and development practice, helping the in-
dustry improve through consulting, technology, and
outsourcing solutions. In his role, Henry worked with
90% of the top 20 biopharmaceutical companies and
provided Accenture leadership to industry groups like
TransCelerate and Hever. Henry has published mul-
tiple articles on clinical development and technology
trends, and is a frequent speaker at industry forums.
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer
success, Veeva has more than 375 customers, ranging
from the world’s largest pharmaceutical companies
to emerging biotechs. Veeva is headquartered in the
San Francisco Bay Area, with offices in Europe, Asia,
and Latin America. For more information, visit www.
Vice President of Marketing
Brian brings 28 years of both client and
agency experience to his current role.
Prior to Medac Pharma, he was Director of Marketing at Cornerstone Therapeutics and previously
led the launch efforts for Letairis® at Gilead and for
Axona® at Accera. At Searle, he directed the first unbranded and branded DTC campaigns for Ambien®.
On the agency side, he worked at Klemtner, KPR, and
Med Think Communications.
Medac Pharma, Inc. is a privately held specialty
pharmaceutical company based in Chicago, Illinois.
Backed by medac GmbH, a global pharmaceutical
company that has been operating in 70 countries for
over 40 years, it is independently and aggressively
building operations in the United States, focusing initially on the development and commercialization of
treatments for autoimmune diseases and oncology. By
forming new partnerships and leveraging its parent
company’s strong product pipeline, it has the opportunity to make significant medical advancements that
can help patients live better lives.